Vitamin B6 deficiency is prevalent in primary and secondary myelofibrosis patients
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Hematology"
DOI: 10.1007/s12185-019-02717-8
Abstract: Vitamin B6 (VB6) deficiency contributes to oncogenesis and tumor progression in certain cancers, and is prevalent in cancer patients in general. VB6 is also an essential element of heme synthesis, and deficiency can lead to… read more here.
Keywords: deficient patients; myelofibrosis; secondary myelofibrosis; vb6 deficiency ... See more keywords
Spleen Stiffness Measurement by Using Shear-Wave Elastography as a Predictor of Progression to Secondary Myelofibrosis
Sign Up to like & getrecommendations! Published in 2021 at "Ultrasound Quarterly"
DOI: 10.1097/ruq.0000000000000486
Abstract: Objective Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative diseases that can transform to secondary myelofibrosis (SMF). In this study, we evaluated spleen stiffness using shear-wave elastography (SWE) as a predictor of progression… read more here.
Keywords: spleen stiffness; secondary myelofibrosis; progression; shear wave ... See more keywords
Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18044
Abstract: a peptide a key regulator of iron in an hepcidin levels can restricted erythro-poiesis and anaemia. myeloproliferative neoplasm (MPN) in we in 99 patients 49 and (SMF) Twenty- four of these patients ruxolitinib a JAK1/2… read more here.
Keywords: hepcidin elevated; secondary myelofibrosis; elevated primary; primary secondary ... See more keywords
Cutaneous extramedullary hematopoiesis in a patient with secondary myelofibrosis due to MPL gene mutation
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.16990
Abstract: Dermal extramedullary hematopoiesis (EMH) is seen as a normal process from the first to the fifth month of gestation, and it is a process in which undifferentiated dermal mesenchymal cells retain their hematopoietic potential.1 However,… read more here.
Keywords: hematopoiesis; patient secondary; secondary myelofibrosis; hematopoiesis patient ... See more keywords